Journal
FRONTIERS IN CHEMISTRY
Volume 5, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fchem.2017.00101
Keywords
EGFR; tyrosine kinase inhibitors; anilinopyrtmidine; glycosides; carbohydrate-based drugs
Categories
Funding
- National Thousand Young Talents Program [YC0130518, YC0140103]
- Shanghai Committee of Science and Technology [14431902100]
- Shanghai Pujiang Program [15PJ1401500]
Ask authors/readers for more resources
The synthesis of a series of ribose-modified anilinopyrimidine derivatives was efficiently achieved by utilizing DBU or tBuOLi-promoted coupling of ribosyl alcohols with 2,4,5-trichloropyrimidine as key step. Preliminary biological evaluation of this type of compounds as new EGFR tyrosine kinase inhibitors for combating EGFR L858R/T790M mutant associated with drug resistance in the treatment of non-small cell lung cancer revealed that 3-N-acryloyl-5-O-anilinopyrimidine ribose derivative la possessed potent and specific inhibitory activity against EGER L858R/1790M over WT EGER. Based upon molecular docking studies of the binding mode between compound la and EGFR, the distance between the Michael receptor and the pyrimidine scaffold is considered as an important factor for the inhibitory potency and future design of selective EGFR tyrosine kinase inhibitors against EGFR L858R/T790M mutants.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available